TY - JOUR
T1 - Multidisciplinary treatment of early stage endometrial cancer
AU - Cecere, S. C.
AU - Pisano, C.
AU - Bamias, A.
AU - Di Napoli, M.
AU - Rossetti, S.
AU - Facchini, G.
AU - Tambaro, R.
AU - Pignata, S.
PY - 2013
Y1 - 2013
N2 - Endometrial cancer is a highly curable malignancy when it presents as uterine-confined disease, but the prognosis for metastatic or recurrent endometrial cancer is poor. For those patients which are diagnosed at an early stage, surgery alone may be adequate for cure and clinical outcome is often favorable, with approximately 80 % of cases surviving at 5 years. However, after primary diagnosis and treatment, roughly 20-30% of patients are expected to recur within the following 5 years. Adjuvant treatment for endometrial cancer is not yet clearly defined. FIGO Stage I-III endometrial cancer patients, usually undergo surgery and some of them are offered adjuvant treatment based on risk assessment. Grade, age, stage are considered all independent risk factors for recurrence. Radiotherapy (RT) has been considered the adjuvant treatment of choice for decades, being able to reduce local recurrence rate and improving progression free survival, but without any impact on overall survival. In the last two decades, a shift toward the use of systemic chemotherapy (CT) in addition or instead of radiation has occurred, although few prospective studies have been performed in this field.
AB - Endometrial cancer is a highly curable malignancy when it presents as uterine-confined disease, but the prognosis for metastatic or recurrent endometrial cancer is poor. For those patients which are diagnosed at an early stage, surgery alone may be adequate for cure and clinical outcome is often favorable, with approximately 80 % of cases surviving at 5 years. However, after primary diagnosis and treatment, roughly 20-30% of patients are expected to recur within the following 5 years. Adjuvant treatment for endometrial cancer is not yet clearly defined. FIGO Stage I-III endometrial cancer patients, usually undergo surgery and some of them are offered adjuvant treatment based on risk assessment. Grade, age, stage are considered all independent risk factors for recurrence. Radiotherapy (RT) has been considered the adjuvant treatment of choice for decades, being able to reduce local recurrence rate and improving progression free survival, but without any impact on overall survival. In the last two decades, a shift toward the use of systemic chemotherapy (CT) in addition or instead of radiation has occurred, although few prospective studies have been performed in this field.
KW - Adjuvant chemotherapy
KW - Endometrial cancer
KW - Hormonal therapy
KW - Prognostic factors
KW - Radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=84880167979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880167979&partnerID=8YFLogxK
U2 - 10.2174/18715206113139990111
DO - 10.2174/18715206113139990111
M3 - Article
C2 - 23194422
AN - SCOPUS:84880167979
VL - 13
SP - 861
EP - 871
JO - Anti-Cancer Agents in Medicinal Chemistry
JF - Anti-Cancer Agents in Medicinal Chemistry
SN - 1871-5206
IS - 6
ER -